glutathione s-transferase gst inhibitors human s transferase Hidden Allostery in P1-1 Unveiled by Unnatural Amino Acid Substitutions and Inhibition Studies Schematic representation of the structure – Amount (mg):5mg LOW STOCK TOSOWOONG

glutathione s-transferase gst inhibitors human s transferase Hidden Allostery in P1-1 Unveiled by Unnatural Amino Acid Substitutions and Inhibition Studies Schematic representation of the structure – Amount (mg):5mg LOW STOCK TOSOWOONG

TOSOWOONG

(Study: Ryan et al., 2020) Clinical Applications: It is primarily indicated for obesity management and may not be the first choice for diabetes treatment

LOW STOCK

Amount (mg):5mg

Prohibited by the World Anti-Doping Agency in competition Product Specifications Format: pre-mixed liquid intranasal spray (1:1 BPC-157 to TB-500 ratio per metered amount) Strength: 60 mg total peptide per 30 mL bottle (30 mg BPC-157 + 30 mg TB-500) Purity: ≥99% (HPLC verified, each component) Container: sealed metered nasal spray bottle Certificate of Analysis: lot-specific COA available, with separate purity and identity verification for both component peptides See the FDA Disclosure, Storage Instructions, and RUO tabs for handling, storage, and regulatory information